- Sun Pharma's Q2 FY27 net profit fell 36.2% to Rs 1,988.53 crore due to a one-time loss
- Revenue rose 11.9% YoY to Rs 16,198.71 crore, surpassing market expectations
- EBITDA increased 4.8% to Rs 4,744 crore, while EBITDA margin narrowed to 29.3%
Sun Pharmaceutical Industries on Friday reported its earnings for the second quarter of FY27, with its net profit falling over 36% due to one-time loss, coming below estimates, while revenue beating the expectations.
The pharma major posted consolidated net profit of Rs 1,988.53 crore in the quarter ended September 2026, a fall of 36.2% from Rs 3,117.95 crore in the year-ago period. The bottomline was impacted due to a one-time loss of Rs 1,269 crore during the quarter.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Profit before exceptional items and tax was Rs 4,428.2 crore, up 6.3% YoY.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The company's revenue from operations in Q2FY27 rose 11.9% to Rs 16,198.71 crore from Rs 14,478.31 crore, year-on-year (YoY).
NDTV Profit estimated a net profit of Rs 3,085 crore and a revenue of Rs 15,766 crore.
At the operational level, earnings before interest, taxes, depreciation and amortization (EBITDA) during the quarter increased 4.8% to Rs 4,744 crore from Rs 4,527 crore, YoY. EBITDA margin narrowed to 29.3% from 31.3%, YoY.
R&D investment of the company was Rs 778.4 crore at 4.8% of sales.
India Formulation
Sun Pharma's formulation sales in India were Rs 5,552.3 crore, up by 17.3% from Rs 4,735 crore, YoY, and accounting for 34.5% of total consolidated sales for the quarter.
The company's market share increased to 8.6% from 8.3%, as per the Pharmarack MAT Sept-2026 report.
US Formulations
Formulation sales in the US were $455 million for Q2FY27, registering a decline of 8.2%. US sales accounted for approximately 27% of total consolidated sales.
Emerging Markets (EM) Formulations
Emerging Markets Formulations sales grew 7.6% YoY to $350 million during the September quarter and accounted for 20.7% of total consolidated sales.
Rest of World (ROW) Formulations
Formulation sales in Rest of World (RoW) markets were $241 million for Q2FY27, up by 3.1% and accounted for 14.3% of total consolidated sales for the quarter.
At 2:45 PM, Sun Pharma share price was trading 3.99% higher at Rs 1,833.30 apiece on the BSE.
ALSO READ: Catch Q2 Results Live Updates Here
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
